Development and Validation of a Model to Predict Absolute Vascular Risk Reduction by Moderate-Intensity Statin Therapy in Individual Patients With Type 2 Diabetes Mellitus: The Anglo Scandinavian Cardiac Outcomes Trial, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, and Collaborative Atorvastatin Diabetes Study [Original Articles]
Conclusions—
ARRs of major cardiovascular events by statin therapy can be accurately estimated for individual patients with type 2 diabetes mellitus using a model based on routinely available patient characteristics. There is a wide distribution in ARR that may complement informed decision making.
Clinical Trial Registration—
URL: http://www.clinicaltrials.gov. Unique identifier: NCT00327418 (CARDS) and NCT00000542 (ALLHAT).
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Kaasenbrood, L., Poulter, N. R., Sever, P. S., Colhoun, H. M., Livingstone, S. J., Boekholdt, S. M., Pressel, S. L., Davis, B. R., van der Graaf, Y., Visseren, F. L. J., on behalf of the CARDS, ALLHAT, and ASCOT Investigators Tags: Lipids and Cholesterol, Diabetes, Type 2, Primary Prevention, Secondary Prevention Original Articles Source Type: research
More News: Atorvastatin Calcium | Cardiology | Cardiovascular | Cholesterol | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Heart | Heart Attack | Lipitor | PET Scan | Pravastatin | Statin Therapy | Statistics | Study | Zivast